Harnessing Microbial Recognition and Host Defense Responses To Fight Cancer
Manhattan BioSolutions is a private biotech company focused on the discovery and development of the next-generation immunotherapy for the treatment or potential prevention of cancer. We develop novel anti-cancer therapies that leverage natural ability of innate immunity to defend human body against invading pathogens or injured cells
In the News
Scientific Platforms
Synthetic Microbes
The sMIST (Synthetic Microbial Immune Stimulators) platform is based on genetically engineered microbes – “living drugs” that express immunomodulatory molecules or target mutated tumor antigens
Monoclonal Antibodies
Our novel monoclonal antibodies target Innate Immune Sensors – immunoregulatory receptors that recognize pathogens or endogenous molecules released as a result of tissue injury or inflammation
Get in touch !
If you are interested in exploring innate immunity and its translation into human therapies, or if your technology could advance the science, please contact us at ir@manhattanbiosolutions.com